Compounds for inhibiting egfr kinase, preparation methods and uses thereof

A compound of general formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• X is selected from the group consisting of N and CH;
• R1 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, —C(O)OR8 and CN;
• R2 is selected from the group consditing of C1-6 alkyl, C3-6 cycloalkyl and C1-6 haloalkyl;
• R3 is selected from the group consisting of —NR9(CH2)2NR9′R9″ and
• R4 is
• R5, R6 and R7 are independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy and CN;
• R8 is selected from the group consisting of hydrogen, C1-6 alkyl and C1-6 haloalkyl;
• R9 is selected from the group consisting of hydrogen, C1-6 alkyl and C1-6 haloalkyl;
• R9′ and R9″ are independently selected from the group consisting of hydrogen, C1-6 alkyl and C1-6 haloalkyl, or R9′ and R9″ together with the nitrogen connected thereto form a heterocycle, the heteroclcle is unsubstituted or optionally substituted with 1-3 groups selected from the group consisting of halogen, C1-6 alkyl and C1-6 haloalkyl;
• R10 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl and —CH2NR12′R12″;
• R11 is selected from the group consisting of hydrogen, halogen and C1-6 alkyl;
• and
• R12 and R12′ are independently selected from the group consisting of hydrogen, C1-6 alkyl and C1-6haloalkyl, or R12′ and R12″ together with the nitrogen connected thereto form a heterocycle, the heteroclcle is unsubstituted or optionally substituted with 1-3 groups selected from the group consisting of halogen, C1-6 alkyl and Cl-6 haloalkyl.